Protara R&D Chief Disposes Small Stake as Company Advances TARA-002 Trial
Jacqueline Zummo, Chief R&D Officer at Protara Therapeutics (NASDAQ: TARA), sold 1,134 shares on April 8, 2026 under a pre-established Rule 10b5-1 plan. The transaction, worth $6,123 at $5.40 per share, leaves her with 94,827 shares. The insider move coincides with updated interim results from the Phase 2 ADVANCED-2 trial for TARA-002 and an announ…